Dr.ObesityLA said:

The dose-response is real but shallow at the top.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

NurseKim_ATL said:

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured…

Thank you for spelling out the reasoning rather than just the conclusion. Taking it to my next appointment.

Dr.ObesityLA said:

The dose-response is real but shallow at the top.

Pushing back on Dr.ObesityLA here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

fiona_VT said:

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Compounding pharmacy red flag checklist for compounded supply — if ANY of these apply, find a different source:

1. No verifiable physical address
2. No pharmacist available for consultation
3. COA not available or clearly template/fake
4. Prices dramatically below market ($30-40/month = suspicious)
5. No prescription required
6. Ships without cold pack or temperature control
7. No batch/lot numbers on product labeling
8. Pushes "research use only" products for human injection

Your health depends on product quality. Don't cut corners on source verification.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.